Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
Biolase, Inc. (NASDAQ: BIOL) is a leading medical device company specializing in the development, manufacturing, marketing, and sales of advanced laser systems used in dentistry and medicine. Based in the United States, the company is recognized globally for its innovative dental laser technologies that enhance dental care by enabling clinicians to perform a wide range of minimally invasive procedures, reducing patient pain, fear, and anxiety typically associated with dental treatments.
Biolase’s flagship products are categorized into two primary groups: Waterlase (all-tissue) systems and Diode (soft-tissue) systems. These products cater to various dental professionals, including general dentists, periodontists, endodontists, and oral surgeons, allowing them to execute procedures ranging from simple restorations to complex surgical interventions. The company’s revenue is predominantly derived from the U.S. market, but its impact is felt worldwide, having sold over 47,700 laser systems across more than 80 countries.
In recent developments, Biolase has expanded its educational initiatives, recognizing the growing demand for knowledge in dental laser technologies. The company launched new courses through its Education.Biolase.com portal, offering both in-person and virtual training through the Waterlase Academy and Epic Diode Academy. This educational expansion includes specialized courses in endodontics, periodontics, pediatric dentistry, and facial esthetics. Notably, Biolase unveiled the Waterlase iPlus Premier Edition at the Chicago Midwinter Meeting 2024, which represents a significant innovation in all-tissue laser systems.
Financially, Biolase has shown resilience amidst challenging market conditions. For the year ending December 31, 2023, the company reported net revenues of $49.2 million, a slight increase compared to the previous year. Despite a decrease in U.S. laser sales, the company saw a 31% increase in U.S. consumables and other revenue. The company is actively optimizing its operations and has undertaken cost-reduction measures, including a workforce reduction projected to save approximately $2.5 million annually.
Looking ahead, Biolase continues to focus on driving the adoption of its dental laser systems and expanding its educational offerings. The company aims to achieve long-term growth and profitability through strategic initiatives and product innovations. For further updates and information, visit www.biolase.com or follow Biolase on various social media platforms.
BIOLASE, Inc. (NASDAQ: BIOL) reported a significant rebound in its third quarter 2020 results, with total revenue reaching $6.5 million, a 124% increase sequentially from Q2, although down 24% year over year. U.S. laser revenue rose 16% year over year to $2.7 million, driven by higher average selling prices. Operating expenses decreased by 24% to $5.9 million, leading to a reduced operating loss of $3.7 million. The company also strengthened its balance sheet via an $18 million equity raise, with cash reserves totaling $19.2 million as of September 30, 2020.
BIOLASE, Inc. (NASDAQ: BIOL) will announce its third quarter 2020 financial results on November 12, 2020, after U.S. market close. A conference call and webcast will take place at 4:30 p.m. ET to discuss the results. U.S./Canada participants can call (800) 367-2403, while international participants can dial +1 334-777-6978. The Conference ID is 9286776. A 30-day audio archive will be available afterward. BIOLASE specializes in dental laser systems, having sold over 41,500 units in over 80 countries, enhancing dental and medical practices.
BIOLASE, Inc. (NASDAQ: BIOL) has released an updated corporate presentation and business overview on M-Vest.com. This platform will serve as a regular update source for investors. The company's innovative laser systems have revolutionized dental practices, with over 41,200 units sold in more than 80 countries. BIOLASE emphasizes its extensive patent portfolio, which includes 261 patents and 52 patent-pending technologies aimed at enhancing patient care and recovery. For more details, visit www.biolase.com.
BIOLASE, Inc. (NASDAQ: BIOL) announced preliminary revenue results for Q3 2020, projecting revenues between $6.4 million to $6.6 million, a notable increase from Q2 2020. U.S. revenue is expected to match Q3 2019 levels as dentist practices reopen and resume operations amid the pandemic. Over 90% of U.S. laser revenue came from new Waterlase sales. The CEO highlighted that 95% of dental offices have reopened, with procedures at 70% of pre-pandemic levels. A webinar featuring dental experts will discuss the advantages of Waterlase technology.
BIOLASE, Inc. (NASDAQ: BIOL) announced an upcoming investor and analyst webinar on October 14, 2020, to showcase the benefits of laser dentistry and its role in reducing infection risks during the COVID-19 pandemic. With 85% of dental offices in the U.S. reopened and procedures at 70% of pre-COVID-19 levels, BIOLASE emphasizes its Waterlase Technology, which minimizes aerosolization by 98%. Esteemed dental experts will participate to discuss growth opportunities and share insights from the recently published McGuire study.
BIOLASE, Inc. (NASDAQ: BIOL) hosted a panel discussion with nearly 400 dental professionals to review a landmark study from the McGuire Institute. The study compared BIOLASE's REPAIR Perio laser protocol to traditional periodontal flap surgery for managing periodontitis. Key findings highlighted superior patient-related outcomes, including less bruising, swelling, and pain with laser treatment, in addition to faster procedure times. The event reflects growing enthusiasm in the dental community regarding laser treatments, indicating potential for future growth in BIOLASE's market presence.
BIOLASE, a leader in dental lasers, announced a presentation by Todd Norbe, President and CEO, and John Beaver, COO and CFO, at the H.C. Wainwright 22nd Annual Global Investor Conference on September 16, 2020, at 11:00 AM PT. The presentation will cover the company’s recent progress and achievements and will include virtual one-on-one meetings with institutional investors. The live webcast can be accessed at this link or on BIOLASE's investor relations website, showcasing their innovative dental technology.
BIOLASE, Inc. (NASDAQ: BIOL) will present an overview of the company and its recent progress at the Colliers & Co. Institutional Investor Conference on September 10, 2020. Executives Todd Norbe and John Beaver will engage in virtual meetings with institutional investors. Norbe expressed optimism regarding BIOLASE's positioning for growth post-COVID-19, citing enthusiasm for recent study results on Waterlase-assisted treatment of periodontitis. BIOLASE has sold over 41,200 dental laser systems globally, leveraging 261 patented and 52 patent-pending technologies to improve dental procedures.
Foothill Ranch, CA / ACCESSWIRE / August 24, 2020 - BIOLASE, Inc. (NASDAQ:BIOL) announced that President and CEO Todd Norbe and CFO John Beaver will present at the LD Micro 500 virtual conference on September 3, 2020, at 1:40 PM PT. Investors can also schedule one-on-one meetings from September 1-3.
The conference runs from September 1-4 and showcases updates from 500 prominent micro-cap companies. The presentation will be accessible via BIOLASE's investor relations page. For more details, visit www.biolase.com.
BIOLASE, Inc. (NASDAQ: BIOL) announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million after an $18 million Rights Offering. Nasdaq granted an additional 180-day grace period for the company to meet the $1.00 minimum bid price requirement, expiring on February 16, 2021. CFO John Beaver has been promoted to Chief Operating Officer, maintaining his financial duties. The company's laser systems support safe dental practices amid the COVID-19 pandemic, producing 98% less aerosols than traditional methods.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
What are the main products offered by Biolase, Inc.?
Where can I find educational resources on Biolase's dental lasers?
How has Biolase performed financially in recent years?
What recent innovations has Biolase introduced?
What is Biolase's strategy for long-term growth?
What markets does Biolase primarily serve?
What is the significance of Biolase's educational initiatives?
How can investors stay informed about Biolase's financial performance?
What are the advantages of using Biolase's laser systems in dentistry?
Where can I find more information about Biolase's products and updates?
